11/03/2026
The Cancer Care and Research Center has two newly activated clinical trials:
⮩ CA266-0002: ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With
PD-L1 = 50%
The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 = 50% by comparing Profession-Free Survival (as assessed by Blinded Independent Central Review (BICR) according to RECIST) and Overall Survival of pumitamig vs pembrolizumab in the patient population.
Lead Research Staff: Logan Humphrey & Barbie Gildenzopf, RN
ClinicalTrials.gov: NCT07361510
⮩ D702GC00001: A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients With PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04)
This clinical trial aims to demonstrate the efficacy of relvegostomig relative to pembrolizumab by assessing Overall Survival and Progression-Free Survival.
Lead Research Staff: Logan Humphrey & Maria Rozumialski, RN
ClinicalTrials.gov: NCT06868277
⮩ Both studies are led by Dr. Adedayo Onitilo and Dr. Seth Fagbemi at our Weston, Stevens Point, and Marshfield locations but eligible participants can enroll at oncology treatment centers across the state.
⮩ To learn more about these studies, visit the ClinicalTrials.gov links above or contact the lead research staff listed for each trial.